← Leaderboards
Garland Ross Marshall
Washington University
$5,436,080
Attributed
$7,820,587
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,820,587 · 14
By mechanism
R01$7,498,399 · 5
P41$322,188 · 9
Top collaborators
- Allan Doctor6 shared
- Timothy J Mcmahon6 shared
Most similar at Washington University
Same institution · by research overlap
- Allison Willis$6,981,326
- Steven J Mennerick$16,806,295
- Nuri B Farber$2,303,846
- Virginia L Miller$17,757,785
- Hong Chen$16,244,124
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructureBaseDesignSourceEvaluationAffinityVirtualSignal TransductionFunctional DisorderMimeticsBinding (Molecular Function)Molecular RecognitionInhibitor/AntagonistMolecular DynamicsUnited States National Institutes Of HealthGrantFundingResourcesComputer SimulationLipidsMolecularAmino AcidsMarshalNovel Therapeutics
Grant awards (31)
SEPSIS-INDUCED RED CELL DYSFUNCTION (SIRD)$379,658
R01 · FY2019 · GM
SEPSIS-INDUCED RED CELL DYSFUNCTION (SIRD)$739,727
R01 · FY2018 · GM
SEPSIS-INDUCED RED CELL DYSFUNCTION (SIRD)$765,117
R01 · FY2017 · GM
SEPSIS-INDUCED RED CELL DYSFUNCTION (SIRD)$787,957
R01 · FY2016 · GM
DISCOVERY OF NEW THERAPEUTICS FOR DRUG-FREE REMISSION OF HIV$315,015
R01 · FY2016 · GM · contact PI
SEPSIS-INDUCED RED CELL DYSFUNCTION (SIRD)$65,833
R01 · FY2016 · GM
SEPSIS-INDUCED RED CELL DYSFUNCTION (SIRD)$838,469
R01 · FY2015 · GM
DISCOVERY OF NEW THERAPEUTICS FOR DRUG-FREE REMISSION OF HIV$315,015
R01 · FY2015 · GM · contact PI
DISCOVERY OF NEW THERAPEUTICS FOR DRUG-FREE REMISSION OF HIV$398,590
R01 · FY2014 · GM · contact PI
DISCOVERY OF NEW THERAPEUTICS FOR DRUG-FREE REMISSION OF HIV$50,000
R01 · FY2014 · GM · contact PI
DISCOVERY OF NEW THERAPEUTICS FOR DRUG-FREE REMISSION OF HIV$402,768
R01 · FY2013 · GM · contact PI
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS$1,094
P41 · FY2011 · RR · contact PI
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS$1,091
P41 · FY2010 · RR · contact PI
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS$771
P41 · FY2009 · RR · contact PI
Heterochiral Dipeptides of Chimeric Cyclic Amino Acids$304,650
R01 · FY2008 · GM · contact PI
HYBRID PROTEIN ENGINEERING$473
P41 · FY2008 · RR · contact PI
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS$473
P41 · FY2008 · RR · contact PI
Heterochiral Dipeptides of Chimeric Cyclic Amino Acids$329,092
R01 · FY2007 · GM · contact PI
MOLECULAR RECOGNITION IN DRUG DESIGN$1,695
P41 · FY2007 · RR · contact PI
TARGETING PROTEIN INTERACTIONS AND DESIGNING CHIMERIC PROTEINS$299
P41 · FY2007 · RR · contact PI
HYBRID PROTEIN ENGINEERING$299
P41 · FY2007 · RR · contact PI
Heterochiral Dipeptides of Chimeric Cyclic Amino Acids$391,874
R01 · FY2006 · GM · contact PI
Heterochiral Dipeptides of Chimeric Cyclic Amino Acids$321,300
R01 · FY2005 · GM
Heterochiral Dipeptides of Chimeric Cyclic Amino Acids$59,734
R01 · FY2005 · GM
REVERSE TURN RECOGNITION AND MIMETIC PROPENSITY$281,925
R01 · FY2002 · GM
COMPUTER AIDED DRUG DESIGN (CORE)$157,506
P41 · FY2002 · RR
REVERSE TURN RECOGNITION AND MIMETIC PROPENSITY$279,376
R01 · FY2001 · GM
COMPUTER AIDED DRUG DESIGN (CORE)$157,506
P41 · FY2001 · RR
REVERSE TURN RECOGNITION AND MIMETIC PROPENSITY$265,607
R01 · FY2000 · GM
CHARACTERIZATION OF THE RHODOPSIN/TRANSDUCIN INTERFACE$206,692
R01 · FY2000 · EY
COMPUTER AIDED DRUG DESIGN (CORE)$981
P41 · FY2000 · RR